Biomerica : Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome - Form 8-K

Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome



... | February 10, 2022

Related Keywords

United States ,California ,Rome ,Lazio ,Italy ,Michigan ,Irvine ,Americans ,American ,John Nesbett Jennifer Belodeau ,Doug Drossman ,Zack Irani ,Brian Lacy ,Jerome Foundation ,University Of North Carolina ,Nasdaq ,University Of Michigan ,Exchange Commission ,Company Annual Report On Form ,Company Infoods ,Beth Israel Deaconess Medical Center Inc ,Laboratory Developed Test ,Harvard Medical School Teaching Hospital ,Biomerica Inc ,Biomerica Announces Positive Topline Results ,Endpoint Clinical Trial ,Irritable Bowel ,Guided Therapy ,Mayo Clinic ,Houston Methodist Hospital ,Irritable Bowel Syndrome ,Topline Results ,Subject Global Assessment ,Global Improvement Scale ,Chief Executive Officer Zack Irani ,President Emeritus ,Professor Emeritus ,North Carolina ,Scientific Advisory Board ,American Journal ,Private Securities Litigation Reform Act ,Annual Report ,Jennifer Belodeau ,Biomerica ,Nc Stock Exchange ,News ,Information ,Press Release ,Nnounces ,Positive ,Topline ,Results ,Rom ,The ,Ndpoint ,Linical ,Trial ,F ,Its ,Jobs ,Treatment ,Or ,Patients ,Ith ,Irritable ,Owel Bmra Us09061h3075 ,